PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors.

Cancers (Basel) · 2020 · PMC7280986 · PMID 32429368

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

did not reach statistical significancep = 0.057so close (0.05 < p ≤ 0.1)

have documented that elderly treated with nivolumab seem to have a survival advantage compared to younger patients, although the difference did not reach statistical significance ( p = 0.057) [ 19 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.